News
Anne Blaes, MD, and Claudio Brunstein, MD, PhD, appointed to leadership positions at the Twin Cities’ only National Cancer Institute (NCI) designated comprehensive cancer center
Dr. Anne Blaes has accepted the role of co-leader of the Screening, Prevention, Etiology and Cancer Survivorship (SPECS) Research Program at the Masonic Cancer Center, University of Minnesota. Blaes is an Associate Professor of Medicine…
U of M opens a new clinical trial studying the effects of COVID-19 on cancer patients
The University of Minnesota, which is already at the forefront of COVID-19 research, has opened a new trial to study the short and long-term effects of the novel coronavirus on cancer patients. The study is a partnership between the…
Research breakthrough on specific form of cell death may overcome chemoresistance
Institute researchers find evidence in favor of necroptotic therapies
November 2, 2020 (Austin, Minn.) – Dr. Ilana Chefetz, head of the Cancer Stem Cells & Necroptosis lab at The Hormel Institute, published a review article focusing…
Breakthrough research using light-activated proteins for targeted therapy
Discoveries may impact future brain tumor therapy and treatment for hospital-acquired infections
October 27, 2020 (Austin, Minn.) – The Nucleotide Metabolism & Drug Discovery lab at The Hormel Institute, led by Dr. Jarrod French,…
Breakthrough research using light-activated proteins for targeted therapy
Discoveries may impact future brain tumor therapy and treatment for hospital-acquired infections
October 27, 2020 (Austin, Minn.) – The Nucleotide Metabolism & Drug Discovery lab at The Hormel Institute, led by Dr. Jarrod French,…
U of M opens first of its kind Phase I/II clinical trial to treat metastatic gastrointestinal epithelial cancer using CRISPR edited immune cells
The University of Minnesota has opened a new and innovative clinical trial for the treatment of metastatic gastrointestinal epithelial cancer. The Phase I/II clinical trial, which will use the revolutionary CRISPR/Cas9 System, has opened…
U of M opens first of its kind Phase I/II clinical trial to treat metastatic gastrointestinal epithelial cancer using CRISPR edited immune cells
MINNEAPOLIS, MN - The University of Minnesota has opened a new and innovative clinical trial for the treatment of metastatic gastrointestinal epithelial cancer. The Phase I/II clinical trial, which will use the revolutionary CRISPR/Cas9…
U of M opens first of its kind Phase I/II clinical trial to treat metastatic gastrointestinal epithelial cancer using CRISPR edited immune cells
MINNEAPOLIS, MN - The University of Minnesota has opened a new and innovative clinical trial for the treatment of metastatic gastrointestinal epithelial cancer. The Phase I/II clinical trial, which will use the revolutionary CRISPR/Cas9…
University of Minnesota Researchers Awarded $2.06M Grant from The NCI
Leaders in the Program in Health Disparities Research (PHDR) and the Masonic Cancer Center, University of Minnesota recently received a $2,063,688 award from the National Cancer Institute/National Institutes of Health for their R25 project…
FDA Grants Orphan Drug Designation for New Treatment for Life-Threatening Acute GVHD Developed at the University of Minnesota
The FDA has granted Orphan Drug Designation to urinary-derived human chorionic gonadotropin and epidermal growth factor (uhCG/EGF, most commonly available as Pregnyl®) for the treatment of acute graft-versus-host-disease (GVHD). This…